Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y₁₂ receptor antagonist

References

• Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation82, 47–59 (1990).
   Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJet al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358, 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rdet al.; CREDO investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288, 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CMet al.; CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352, 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YPet al.; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366, 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CMet al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294, 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation102, 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo Eet al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol.49, 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost.102, 7–14 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am. Heart J.156, S23–S28 (2008).
   Web of Science ®Google Scholar
• Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets12, 443–447 (2001).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. ADP receptor antagonism: what’s in the pipeline? Am. J. Cardiovasc. Drugs7, 423–432 (2007).
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc. Ther.27, 259–274 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J.156, S10–S15 (2008).
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J.27, 1038–1047 (2006).
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Nilsson L, Berntsson Pet al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J. Thromb. Haemost.7, 1556–1565 (2009).
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Berntsson P, Wissing BM. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells. Arterioscler. Thromb. Vasc. Biol.28, e72 (2008).
   Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem. Thromb. Hemost.31, 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Patil SBG, Norman KE, Robins SJet al. Inhibition of thrombosis by AZD6140 via selective blockade of the P2Y12 receptor in a murine laser-injury model. J. Thromb. Haemost.5, PW632 (2007).
   Google Scholar
• van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA. Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis Research124, 565–571 (2009).
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey Aet al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem.42, 213–220 (1999).
   PubMed Web of Science ®Google Scholar
• Leff P, Robertson MJ, Humphries RG. The role of ADP in thrombosis and the therapeutic potential of P2T-receptor antagonists as novel antithrombotic agents. In: Purinergic Approaches in Experimental Therapeutics. Jacobson A, Jarvis MF (Eds). Wiley-Liss, NY, USA, 203–216 (1997).
   Google Scholar
• Humphries RG, Nicol AK, Tomlinson Wet al. Effect of the novel P2T receptor antagonist, AR-C69931MX, on thrombosis and haemostasis in the dog: comparison with GPIIb/IIIa antagonists. Haematologica85, 91–92 (2000).
   Google Scholar
• Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140 – an oral reversible ADP receptor antagonist. Haematologica989, 14–15 (2004).
   Google Scholar
• Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZP6140. Eur. Heart J.27, P4556 (2006).
   Google Scholar
• Cannon CP, Husted S, Harrington RAet al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol.50, 1844–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RAet al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol.50, 1852–1856 (2007).
   PubMed Web of Science ®Google Scholar
• Gurbel P, Bliden K, Butler Ket al. A randomized double-blind study to assess the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. Circulation120, S1143 (2009).
   Google Scholar
• Bliden K, Tantry U, Antonino Met al. Differential effect of ticagrelor versus clopidogrel on the prevalence of high on-treatment platelet reactivity: results from the ONSET–OFFSET study. Circulation120, S1172–S1173 (2009).
   Google Scholar
• Storey RF, Bliden K, Patil SB. The effect of ticagrelor on cardiopulmonary function in oatients with stable coronary artery disease. Circulation120, S1145 (2009).
   Google Scholar
• Gurbel P, Bliden K, Antonino M. The effect of ticagrelor in stable coronary artery disease patients nonresponsive to clopidogrel: The RESPOND study. Circulation120, S1173 (2009).
   Google Scholar
• James S, Akerblom A, Cannon CPet al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J.157, 599–605 (2009).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj Aet al.; PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361, 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Rao AK, Pratt C, Berke Aet al. Thrombolysis in Myocardial Infarction (TIMI) trial – Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am. Coll. Cardiol.11, 1–11 (1988).
   PubMed Web of Science ®Google Scholar
• Bovill EG, Terrin ML, Stump DCet al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann. Intern. Med.115, 256–265 (1991).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results from the PLATelet inhibition and patient Outcomes (PLATO) trial. Presented at: American Heart Association 2009. Orlando, FL, USA, 15–18 November 2009 (Final Program Number LBCT.01).
   Google Scholar
• Storey RF, Angiolillo DJ, Patil SB. Maintenance treatment with ticagrelor yields greater and more consistent inhibition of platelet function compared to clopidogrel in patients with acute coronary syndromes: results from the PLATO PLATELET substudy. Circulation120, S1027 (2009).
   PubMed Web of Science ®Google Scholar
• Storey RF, Patil SB, Ecob R. More rapid and consistent inhibition of platelet aggregation is achieved by loading with ticagrelor compared to clopidogrel in patients with acute coronary syndromes: results from the PLATO PLATELET substudy. Circulation120, S1102 (2009).
   Google Scholar
• Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation103, 201–206 (2001).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am. J. Cardiol.103(Suppl.), 40A–51A (2009).
   PubMed Web of Science ®Google Scholar